90Y-edotreotide for metastatic carcinoid refractory to octreotide.

ABSTRACT:

Purpose

Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening. Although symptom relief is available with octreotide, the disease eventually becomes refractory to octreotide, leaving no proven treatment options. The goal of this study was to evaluate the clinical effect of using (90)Y-edotreotide to treat symptomatic patients with carcinoid tumors.

Patients and methods

Patients enrolled had metastatic carcinoid, at least one sign/symptom refractory to octreotide, and at least one measurable lesion. Study treatment consisted of three cycles of 4.4 GBq (120 mCi) (90)Y-edotreotide each, once every 6 weeks.

Results

Ninety patients were enrolled in the study. Using Southwest Oncol

SUBMITTER: Bushnell DL 

PROVIDER: S-EPMC4872330 | biostudies-literature | 2010 Apr

REPOSITORIES: biostudies-literature